Detailed description of the study population
| Variable . | Overall (n = 2473) . | MRD at day 29 . | ||||
|---|---|---|---|---|---|---|
| <0.01% (n = 1788) . | 0.01% ≤ MRD < 0.10% (n = 281) . | 0.10% ≤ MRD < 1.0% (n = 230) . | 1.0% ≤ MRD < 10.0% (n = 123) . | ≥10.0% (n = 51) . | ||
| Age, mean (SD) | 10.5 (5.7) | 9.8 (5.5) | 11.3 (6.1) | 12.4 (5.3) | 13.1 (5.2) | 13.9 (4.6) |
| Age group (y) | ||||||
| <10 | 823 (33.3%) | 663 (37.1%) | 81 (28.8%) | 48 (20.9%) | 26 (21.1%) | 5 (9.8%) |
| ≥10 | 1650 (66.7%) | 1125 (62.9%) | 200 (71.2%) | 182 (79.1%) | 97 (78.9%) | 46 (90.2%) |
| Gender | ||||||
| Male | 1350 (54.6%) | 944 (52.8%) | 164 (58.4%) | 137 (59.6%) | 71 (57.7%) | 34 (66.7%) |
| Female | 1123 (45.4%) | 844 (47.2%) | 117 (41.6%) | 93 (40.4%) | 52 (42.3%) | 17 (33.3%) |
| Treatment | ||||||
| HD-MTX | 1237 (50.0%) | 915 (51.2%) | 132 (47.0%) | 109 (47.4%) | 59 (48.0%) | 22 (43.1%) |
| C-MTX | 1236 (50.0%) | 873 (48.8%) | 149 (53.0%) | 121 (52.6%) | 64 (52.0%) | 29 (56.9%) |
| WBC (×109/L), median (min, max) | 25 (0.3, 1306) | 25.3 (0.3, 1306) | 27.4 (0.8, 495.5) | 20.8 (0.4, 900) | 18.4 (1, 616) | 62.8 (0.9, 845) |
| WBC | ||||||
| <50 × 109/L | 1398 (56.5%) | 1007 (56.3%) | 158 (56.2%) | 141 (61.3%) | 71 (57.7%) | 21 (41.2%) |
| ≥50 × 109/L | 1075 (43.5%) | 781 (43.7%) | 123 (43.8%) | 89 (38.7%) | 52 (42.3%) | 30 (58.8%) |
| CNS status | ||||||
| CNS1 | 2129 (86.1%) | 1547 (86.5%) | 237 (84.3%) | 199 (86.9%) | 103 (83.7%) | 43 (84.3%) |
| CNS2 | 343 (13.9%) | 241 (13.5%) | 44 (15.7%) | 30 (13.1%) | 20 (16.3%) | 8 (15.7%) |
| TEL-AML1 | 331 (15.6%) | 291 (18.9%) | 29 (11.9%) | 6 (3.1%) | 5 (4.8%) | |
| MLL | 58 (2.8%) | 41 (2.7%) | 15 (6.4%) | 2 (5.1%) | ||
| Trisomy 4 and 10 | 360 (17.2%) | 269 (17.8%) | 49 (20.3%) | 29 (14.9%) | 10 (9.6%) | 3 (7.9%) |
| Day 15 morphology (SER) | 265 (10.7%) | 62 (3.5%) | 40 (14.2%) | 59 (25.7%) | 60 (48.8%) | 44 (86.3%) |
| Variable . | Overall (n = 2473) . | MRD at day 29 . | ||||
|---|---|---|---|---|---|---|
| <0.01% (n = 1788) . | 0.01% ≤ MRD < 0.10% (n = 281) . | 0.10% ≤ MRD < 1.0% (n = 230) . | 1.0% ≤ MRD < 10.0% (n = 123) . | ≥10.0% (n = 51) . | ||
| Age, mean (SD) | 10.5 (5.7) | 9.8 (5.5) | 11.3 (6.1) | 12.4 (5.3) | 13.1 (5.2) | 13.9 (4.6) |
| Age group (y) | ||||||
| <10 | 823 (33.3%) | 663 (37.1%) | 81 (28.8%) | 48 (20.9%) | 26 (21.1%) | 5 (9.8%) |
| ≥10 | 1650 (66.7%) | 1125 (62.9%) | 200 (71.2%) | 182 (79.1%) | 97 (78.9%) | 46 (90.2%) |
| Gender | ||||||
| Male | 1350 (54.6%) | 944 (52.8%) | 164 (58.4%) | 137 (59.6%) | 71 (57.7%) | 34 (66.7%) |
| Female | 1123 (45.4%) | 844 (47.2%) | 117 (41.6%) | 93 (40.4%) | 52 (42.3%) | 17 (33.3%) |
| Treatment | ||||||
| HD-MTX | 1237 (50.0%) | 915 (51.2%) | 132 (47.0%) | 109 (47.4%) | 59 (48.0%) | 22 (43.1%) |
| C-MTX | 1236 (50.0%) | 873 (48.8%) | 149 (53.0%) | 121 (52.6%) | 64 (52.0%) | 29 (56.9%) |
| WBC (×109/L), median (min, max) | 25 (0.3, 1306) | 25.3 (0.3, 1306) | 27.4 (0.8, 495.5) | 20.8 (0.4, 900) | 18.4 (1, 616) | 62.8 (0.9, 845) |
| WBC | ||||||
| <50 × 109/L | 1398 (56.5%) | 1007 (56.3%) | 158 (56.2%) | 141 (61.3%) | 71 (57.7%) | 21 (41.2%) |
| ≥50 × 109/L | 1075 (43.5%) | 781 (43.7%) | 123 (43.8%) | 89 (38.7%) | 52 (42.3%) | 30 (58.8%) |
| CNS status | ||||||
| CNS1 | 2129 (86.1%) | 1547 (86.5%) | 237 (84.3%) | 199 (86.9%) | 103 (83.7%) | 43 (84.3%) |
| CNS2 | 343 (13.9%) | 241 (13.5%) | 44 (15.7%) | 30 (13.1%) | 20 (16.3%) | 8 (15.7%) |
| TEL-AML1 | 331 (15.6%) | 291 (18.9%) | 29 (11.9%) | 6 (3.1%) | 5 (4.8%) | |
| MLL | 58 (2.8%) | 41 (2.7%) | 15 (6.4%) | 2 (5.1%) | ||
| Trisomy 4 and 10 | 360 (17.2%) | 269 (17.8%) | 49 (20.3%) | 29 (14.9%) | 10 (9.6%) | 3 (7.9%) |
| Day 15 morphology (SER) | 265 (10.7%) | 62 (3.5%) | 40 (14.2%) | 59 (25.7%) | 60 (48.8%) | 44 (86.3%) |
AML, acute myeloid leukemia; CNS, central nervous system; MLL, mixed-lineage leukemia; WBC, white blood cell.